Tozorakimab

Summary

Tozorakimab (CHEMBL4650490) is a phase-3 clinical-stage antibody; indicated across 6 conditions including chronic obstructive pulmonary disease and atopic eczema.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 6 conditions
• Clinical trials: 15

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650490
Name	Tozorakimab
Type	Antibody
Max phase	3

Also known as: Medi 3506, MEDI-3506, Medi3506, MEDI3506, Tozorakimab, TOZORAKIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
chronic obstructive pulmonary disease	3	MONDO:0005002	EFO:0000341
atopic eczema	2	MONDO:0004980	EFO:0000274
diabetic kidney disease	2	MONDO:0005016	EFO:0000401
chronic bronchitis	2	MONDO:0005607	EFO:0006505
asthma	2	MONDO:0004979	MONDO:0004979
dermatitis	1	MONDO:0002406	HP:0011123

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE2	6
PHASE3	5
PHASE1	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05624450	PHASE3	RECRUITING	Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05742802	PHASE3	ACTIVE_NOT_RECRUITING	Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
NCT06040086	PHASE3	ACTIVE_NOT_RECRUITING	Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
NCT05158387	PHASE3	COMPLETED	Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
NCT05166889	PHASE3	COMPLETED	Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
NCT06897748	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils
NCT06932263	PHASE2	RECRUITING	Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
NCT04170543	PHASE2	COMPLETED	A Phase 2b Diabetic Kidney Disease Study
NCT04212169	PHASE2	COMPLETED	Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis
NCT04570657	PHASE2	COMPLETED	Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma
NCT04631016	PHASE2	COMPLETED	A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis
NCT03096795	PHASE1	COMPLETED	Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants
NCT05070312	PHASE1	COMPLETED	Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese Participants
NCT06304961	PHASE1	COMPLETED	A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers
NCT06908577	PHASE1	COMPLETED	An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).